



Acquisitions of own shares and disposals of own shares

Brussels (Belgium), 12 March 2021 – 20:00 (CET) – regulated information

Acquisitions of own shares

In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, UCB SA/NV (“UCB” or the “Company”) (Euronext Brussels: UCB) hereby discloses certain information in relation to its Share Repurchase Program 2021.

Under this program, UCB has requested a financial intermediary to repurchase up to 750 000 UCB shares on its behalf under the terms of an initial discretionary mandate agreement with validity until 25 June 2021, effective as from 8 March 2021, to cover current and future obligations under UCB's Long Term Incentive Plans for its personnel.

In the framework of this Share Repurchase Program 2021, UCB repurchased 147 138 UCB shares on Euronext Brussels in the period from 8 March 2021 up to and including 11 March 2021, as follows:

Date of repurchase	Number of shares	Average Price Paid	Total	Lowest Price Paid	Highest Price Paid
08 March 2021	33.937	€ 78,20	€ 2.653.717,29	€ 77,40	€ 79,10
09 March 2021	37.470	€ 79,50	€ 2.979.018,63	€ 77,34	€ 80,56
10 March 2021	37.859	€ 80,14	€ 3.033.880,18	€ 80,08	€ 80,80
11 March 2021	37.872	€ 79,78	€ 3.021.257,74	€ 78,94	€ 80,66

Disposal of own shares

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long Term Incentive Program of the UCB Group, as follows:

Date of transaction	Time	LTI Plan	Number of disposed UCB shares	Price
10 March 2021	13:42:36	Stock Option Plan 2011	1.000	€ 26,72

This press release is available on UCB SA/NV's website via the following [link](#).

Investor Relations

Antje Witte,
Investor Relations, UCB
T +32 2 559 94 14,
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 400 people in approximately 40 countries, the company generated revenue of € 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: [@UCB_news](https://twitter.com/UCB_news)